News Sentiment

MNOV sentiment intelligence

MediciNova Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 56 Balanced news tone 55 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 1.39 Week of 10 Jul 2026

Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.8% over one week, +13.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

MediciNova reaches 200-patient enrollment in ALS study

Market Reaction

Balanced read

66/100 confidence

Primary event Market update 82/100 classification

One-week reaction -2.8% Price reacting lower

Trend fit Trend inactive 13.0% over four weeks

Fair value -12.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 15

Neutral 36

Negative 4

Relevance

Why the article matched

Direct first

Direct company coverage 47

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Stock Titan 8

TradingKey 8

Market source 7

dars.gov.et 6

GlobeNewswire 6

TradingView 5

Investing.com 2

DonanımHaber 2

Event Lens

What the news is about

Classified themes

Market update 33

Earnings 15

Analyst action 3

Guidance 2

Regulatory and legal 1

Capital return 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55

Investing.com Direct company coverage

MediciNova reaches 200-patient enrollment in ALS study

MediciNova Inc. (NASDAQ:MNOV) has successfully reached its target enrollment of 200 patients in the SEANOBI-ALS study for MN-166 (ibudilast), a drug being evaluated for amyotrophic lateral sclerosis. The study, funded by the NIH under the ACT for ALS initiative, provides MN-166 t

Tone: Positive 74/100
Event: Analyst action
Published: 15 Jul 2026 15:44
Source: Investing.com

Market source Direct company coverage

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova announced that it has achieved the target enrollment of 200 patients in its NIH-funded SEANOBI-ALS study, an Expanded Access Program evaluating MN‑166 (ibudilast) for patients with amyotrophic lateral sclerosis (ALS). This program provides MN-166 to ALS patients not el

Tone: Positive 71/100
Event: Analyst action
Published: 15 Jul 2026 11:44
Source: Market source

Stock Titan Direct company coverage

ALS patients ineligible for trials join MediciNova's 200-person study

MediciNova (NASDAQ: MNOV) has achieved the enrollment target of 200 ALS patients in its NIH-funded SEANOBI-ALS Expanded Access Program, which evaluates MN-166 (ibudilast). This program allows ALS patients ineligible for randomized clinical trials to access the investigational dru

Tone: Positive 71/100
Event: Regulatory and legal
Published: 15 Jul 2026 11:44
Source: Stock Titan

Market source Industry context

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 13 Jul 2026 12:30
Source: Market source

MSN Direct company coverage

D Boral Capital maintains MediciNova (MNOV) buy recommendation

D Boral Capital has reaffirmed its buy recommendation for MediciNova (MNOV). This decision reflects continued confidence in the company's prospects. The analyst firm maintains a positive outlook on MediciNova's stock.

Tone: Positive 76/100
Event: Guidance
Published: 09 Jul 2026 07:43
Source: MSN

AD HOC NEWS Direct company coverage

MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress

MediciNova Inc. is a clinical-stage biopharmaceutical company focusing on neurological and inflammatory diseases, with a lead candidate MN-166 in advanced trials. The company's pipeline includes other small-molecule candidates targeting inflammatory pathways and fibrotic processe

Tone: Positive 66/100
Event: Market update
Published: 07 Jul 2026 12:41
Source: AD HOC NEWS

TradingView Direct company coverage

Price to earnings forward of MediciNova, Inc. – TSE:4875

This article provides financial information for MediciNova, Inc. (TSE:4875), specifically focusing on its forward price-to-earnings ratio. It presents various financial data points and indicates that the market was closed at the time of the report. The content appears to be a fin

Tone: Neutral 50/100
Event: Earnings
Published: 05 Jul 2026 19:09
Source: TradingView

dars.gov.et Direct company coverage

Medicinova Inc (MNOV) Holds Steady Near Support After Modest Advance - Factor Crowding

Tone: Neutral 50/100
Event: Market update
Published: 02 Jul 2026 14:31
Source: dars.gov.et

dars.gov.et Direct company coverage

Medicinova Inc (MNOV) Surges 7.6% as Biotech Stock Tests Resistance at $1.49 - Buffered ETF

Tone: Positive 66/100
Event: Market update
Published: 02 Jul 2026 02:33
Source: dars.gov.et

TradingView Direct company coverage

Enterprise value to EBITDA forward of MediciNova, Inc. – NASDAQ:MNOV

This page displays financial information for MediciNova, Inc. (NASDAQ: MNOV), specifically its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of access.

Tone: Neutral 50/100
Event: Market update
Published: 01 Jul 2026 15:40
Source: TradingView

TradingView Direct company coverage

Enterprise value to revenue forward of MediciNova, Inc. – TSE:4875

This article displays the enterprise value to revenue forward for MediciNova, Inc. (TSE:4875) on TradingView. It indicates that the market was closed with no trades at the time of publication and provides financial data for the company.

Tone: Neutral 50/100
Event: Earnings
Published: 01 Jul 2026 10:11
Source: TradingView

Stock Titan Direct company coverage

MediciNova awaits Q3 data as ALS study hits 100 patients

MediciNova (NASDAQ: MNOV) provided a shareholder update highlighting progress in its clinical programs, intellectual property, and investor relations. Key achievements include the completion of the last patient last visit in its MN-001 Phase 2 trial, the enrollment of 100 patient

Tone: Positive 89/100
Event: Market update
Published: 01 Jul 2026 03:40
Source: Stock Titan

Investing.com Direct company coverage

MediciNova completes patient visits in phase 2 NAFLD trial

MediciNova Inc. has completed patient visits for its Phase 2 clinical trial of MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus. The company anticipates releasing initial data in Q3 2026 and expects topline

Tone: Positive 72/100
Event: Guidance
Published: 30 Jun 2026 12:40
Source: Investing.com

Investing.com South Africa Direct company coverage

MediciNova completes patient visits in phase 2 NAFLD trial By Investing.com

MediciNova Inc. has completed patient visits for its Phase 2 clinical trial evaluating MN-001 for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The company expects to release initial data in the third quarter of 2026. Additionally, Med

Tone: Positive 73/100
Event: Earnings
Published: 30 Jun 2026 12:09
Source: Investing.com South Africa

GlobeNewswire Direct company coverage

MediciNova CEO Provides Shareholder Update

MediciNova's CEO, Yuichi Iwaki, provided a shareholder update highlighting significant progress in its clinical programs. Key updates include the completion of the last patient visit in a Phase 2 trial for MN-001 with data expected in Q3 2026, expansion of the SEANOBI study for M

Tone: Positive 73/100
Event: Market update
Published: 30 Jun 2026 12:09
Source: GlobeNewswire

TradingView Direct company coverage

MediciNova, Inc. Actuals & Estimates (NASDAQ:MNOV)

This article provides an overview of MediciNova, Inc. (NASDAQ: MNOV) stock, including its current price, market capitalization, volatility, and historical performance. It also details financial actuals and analyst estimates, covering earnings, revenue, and future forecasts, along

Tone: Neutral 50/100
Event: Earnings
Published: 26 Jun 2026 19:09
Source: TradingView

Stock Titan Direct company coverage

MediciNova (MNOV) director awarded 44,500 stock options

MediciNova Inc. director Nagao Hideki was granted 44,500 stock options for Common Stock, with an exercise price of $1.36 per share, expiring on June 22, 2036. This compensation-related award vests in four equal installments between September 2026 and June 2027, provided Nagao Hid

Tone: Neutral 50/100
Event: Market update
Published: 25 Jun 2026 20:40
Source: Stock Titan

Stock Titan Direct company coverage

MediciNova (MNOV) director receives grant of 44,500 stock options

MediciNova Inc. director Carolyn Beaver received a compensation-related grant of 44,500 stock options with an exercise price of $1.36 per share, expiring on June 22, 2036. The options will vest in four equal installments between September 2026 and June 2027, contingent upon her c

Tone: Neutral 50/100
Event: Market update
Published: 25 Jun 2026 20:40
Source: Stock Titan

Investing.com Canada Direct company coverage

Form 4 MediciNova Inc For: 25 June By Investing.com

This article announces the filing of a Form 4 for MediciNova Inc. on June 25, as reported by Investing.com. It is a brief administrative notice regarding a financial disclosure. The article does not contain additional details about the Form 4's content or the transactions involve

Tone: Neutral 50/100
Event: Market update
Published: 25 Jun 2026 20:40
Source: Investing.com Canada

Stock Titan Direct company coverage

MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant

MediciNova Inc. director Nicole Lemerond was granted 44,500 stock options with an exercise price of $1.36 and an expiration date of June 22, 2036. The options will vest in four equal installments between September 2026 and June 2027, contingent upon her continued service. This gr

Tone: Neutral 50/100
Event: Market update
Published: 25 Jun 2026 20:40
Source: Stock Titan

Stock Titan Direct company coverage

MediciNova (MNOV) 2026 annual meeting voting recap and totals

MediciNova, Inc. held its 2026 annual meeting of stockholders on June 23, 2026, where two director nominees, Hikedi Nagao and Nicole Lemerond, were elected with significant "For" votes. The shareholders also ratified BDO USA, P.C. as the independent registered public accounting f

Tone: Neutral 50/100
Event: Market update
Published: 24 Jun 2026 20:10
Source: Stock Titan

dars.gov.et Direct company coverage